|
Amgen and Advaxis enter global cancer immunotherapies collaboration
|
16 August 2016 |
|
FDA approves first and only single monthly injection for a PCSK9 inhibitor
|
11 July 2016 |
|
Amgen Golden Ticket winners receive lab space and other benefits at QB3@953
|
22 June 2016 |
|
Amgen and UCB announce positive top-line tesults from phase 3 study evaluating romosozumab In men with osteoporosis
|
21 March 2016 |
|
Amgen reacquires all product rights to Prolia® (denosumab), XGEVA® (denosumab) and Vectibix® (panitumumab) from GSK in 48 countries
|
15 December 2015 |
|
FDA approves IMLYGICTM (talimogene laherparepvec) as first oncolytic viral therapy in the US
|
28 October 2015 |
|
Amgen to acquire privately-held Dezima Pharma
|
16 September 2015 |
|
Amgen and Xencor announce strategic collaboration in cancer immunotherapy and inflammation
|
16 September 2015 |
|
European Commission approves Amgen's new cholesterol-lowering medication Repatha™ (evolocumab)
|
23 July 2015 |
|
Amgen announces collaboration with Roche on cancer immunotherapy study with investigational medicines talimogene laherparepvec and atezolizumab
|
02 June 2015 |
|
Amgen receives FDA Breakthrough Therapy Designation for investigational BiTE® antibody blinatumomab in acute lymphoblastic leukemia
|
01 July 2014 |
|
Amgen and Merck announce collaboration To evaluate investigational combination treatment for advanced melanoma
|
05 February 2014 |
|
Amgen Foundation commits $2.5 million in new grants to engage 50,000 students each year in the thrill of scientific inquiry
|
07 November 2013 |
|
Amgen's third quarter 2013 revenues increased 10 percent
|
24 October 2013 |
|
Amgen acquires Filgrastim franchise rights from Roche In 100 markets
|
22 October 2013 |
|
Amgen successfully completes Onyx Pharmaceuticals tender offer
|
02 October 2013 |
|
Amgen and ShanghaiTech University announce plans for Amgen China R&D center
|
25 September 2013 |
|
Amgen to acquire Onyx Pharmaceuticals for $125 per share in cash
|
26 August 2013 |
|
FDA approves Amgen's XGEVA® (denosumab) for the treatment of giant cell tumor of bone
|
16 June 2013 |
|
Amgen and Astellas announce Japan Alliance
|
29 May 2013 |